Wojciech Wojakowski
Latest contributions
Bleeding and thrombotic risk in LAA closure patients
20 May 2026 – From EuroPCR 2026
This session provides a thorough examination of bleeding and thrombotic risks in patients undergoing left atrial appendage (LAA) closure. It reviews risk factors for device-related thrombosis, compares anticoagulation strategies post-procedure, and presents real-world clinical outcomes, particularly in high bleeding risk populations and special groups such as...
Align for the future with structural heart innovations - LIVE case and major trial updates
19 May 2026 – From EuroPCR 2026
Stay abreast of structural heart innovations with expert discussions on best-in-class transcatheter aortic valve implantation (TAVI) practices, including imaging, sizing, and procedural strategies. This session with LIVE case introduces the novel Myval Octapro+ transcatheter heart valve (THV), its design philosophy, and potential clinical benefits, along with...
Rapid fire session on next generation structural heart and valve therapies
18 May 2026 – From EuroPCR 2026
An intensive rapid-fire session presenting the latest advancements in next-generation structural heart and valve therapies, including novel transcatheter systems for aortic and mitral valve repair, innovative solutions for tricuspid regurgitation, and implant-free PFO closure technologies.
Innovation to address unmet clinical needs in transcatheter valve therapies
22 May 2025 – From EuroPCR 2025
Discover innovations addressing unmet clinical needs in transcatheter valve therapies. This session shares case-based experiences including young aortic stenosis patients, mitral regurgitation with annular calcification, and severe tricuspid regurgitation with right ventricular dysfunction, alongside the latest advances in TAVI, TMVR, and tricuspid interventions.
TAVI - Outcomes predictors
22 May 2025 – From EuroPCR 2025
Examine novel predictors of outcomes following TAVI. This session compares a new nutritional risk index against traditional scores for early post-TAVI mortality prediction and evaluates uric acid as a marker for aortic valve calcification and mortality risk in TAVI patients.
New devices for structural interventions
21 May 2025 – From EuroPCR 2025
Discover emerging devices transforming structural heart interventions. This session highlights biomimetic valve designs, new transcatheter aortic valve systems, novel devices for aortic insufficiency, leaflet resection, left atrial appendage closure, and short self-expanding TAVR valves with promising early results.
Enhancing clipping solutions for durable long-term patient outcomes
21 May 2025 – From EuroPCR 2025
This EuroPCR 2025 session delves into the evolving strategies for mitral and tricuspid TEER, backed by fresh data and real-world insights. Review the latest evidence from the TRILUMINATE Pivotal and bRIGHT studies, and see how TR phenotypes can guide patient selection for more durable outcomes. Discover...
